Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Bioharvest Sciences (BHST) over the last 3 years, with Q3 2025 value amounting to $35.2 million.

  • Bioharvest Sciences' Liabilities and Shareholders Equity rose 3626.61% to $35.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year increase of 2341.45%. This contributed to the annual value of $25.0 million for FY2024, which is 6665.11% up from last year.
  • According to the latest figures from Q3 2025, Bioharvest Sciences' Liabilities and Shareholders Equity is $35.2 million, which was up 3626.61% from $27.8 million recorded in Q2 2025.
  • Over the past 5 years, Bioharvest Sciences' Liabilities and Shareholders Equity peaked at $35.2 million during Q3 2025, and registered a low of $15.0 million during Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $26.2 million (2024), whereas its average is $25.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 6665.11% in 2024, then surged by 290.22% in 2025.
  • Over the past 3 years, Bioharvest Sciences' Liabilities and Shareholders Equity (Quarter) stood at $15.0 million in 2023, then surged by 66.65% to $25.0 million in 2024, then surged by 40.75% to $35.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $35.2 million for Q3 2025, versus $27.8 million for Q2 2025 and $26.6 million for Q1 2025.